We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




CE-Marked Immunoassay Rapidly Detects Infection Biomarkers

By LabMedica International staff writers
Posted on 17 Jul 2017
CE mark approval has been given for a point-of-care (POC) test for rapid detection of infection in patients on peritoneal dialysis (PD), enabling early diagnosis and treatment critical for preventing infection-related damage to the peritoneal membrane.

The test, PERiPLEX from Mologic (Bedford, UK), uses a lateral flow immunoassay system that provides results in under 10 minutes, developed especially for use at home by PD patients or their careers to enable early warning of infection, prompting them to contact their healthcare provider to initiate preemptive antibiotic therapy.

There are globally over 200,000 patients being treated with PD as the preferred method for managing severe chronic kidney disease (CKD) or end stage renal disease (ESRD). More...
PD uses the peritoneum in a patient’s abdomen as a dialysis membrane for removing toxins and excess fluid, and to correct electrolyte problems in those with kidney failure.

However, PD is known to have a high rate of associated infections that can lead to peritonitis. Using current methods, diagnosis of infection can take over 24 hours, which risks damage to the peritoneal membrane, or formation of scar tissue can prevent long-term use of PD. PERiPLEX tests samples from PD waste fluid for two critical biomarkers of infection: interleukin-6 (IL-6) and matrix metalloproteinase-8 (MMP-8).

Mark Davis, co-founder and CEO at Mologic commented, “PERiPLEX is the first of a pipeline of products from Mologic to receive CE mark approval. We are developing similar diagnostic tests for a range of disease areas, including sepsis, urinary tract infections and chronic obstructive pulmonary disease (COPD). Each of these tests use lateral flow immunoassay technology to detect a host inflammatory response.”

Related Links:
Mologic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.